These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 26993372)

  • 21. Varenicline treatment for methamphetamine dependence: A randomized, double-blind phase II clinical trial.
    Briones M; Shoptaw S; Cook R; Worley M; Swanson AN; Moody DE; Fang WB; Tsuang J; Furst B; Heinzerling K
    Drug Alcohol Depend; 2018 Aug; 189():30-36. PubMed ID: 29860057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence.
    Heinzerling KG; Swanson AN; Kim S; Cederblom L; Moe A; Ling W; Shoptaw S
    Drug Alcohol Depend; 2010 Jun; 109(1-3):20-9. PubMed ID: 20092966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The cardiovascular and subjective effects of methamphetamine combined with gamma-vinyl-gamma-aminobutyric acid (GVG) in non-treatment seeking methamphetamine-dependent volunteers.
    De La Garza R; Zorick T; Heinzerling KG; Nusinowitz S; London ED; Shoptaw S; Moody DE; Newton TF
    Pharmacol Biochem Behav; 2009 Nov; 94(1):186-93. PubMed ID: 19698734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ibudilast for alcohol use disorder: study protocol for a phase II randomized clinical trial.
    Burnette EM; Baskerville WA; Grodin EN; Ray LA
    Trials; 2020 Sep; 21(1):779. PubMed ID: 32912290
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers.
    Newton TF; Reid MS; De La Garza R; Mahoney JJ; Abad A; Condos R; Palamar J; Halkitis PN; Mojisak J; Anderson A; Li SH; Elkashef A
    Int J Neuropsychopharmacol; 2008 Dec; 11(8):1037-45. PubMed ID: 18664303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Separate and Combined Effects of Naltrexone and Extended-Release Alprazolam on the Reinforcing, Subject-Rated, and Cardiovascular Effects of Methamphetamine.
    Marks KR; Lile JA; Stoops WW; Glaser PE; Hays LR; Rush CR
    J Clin Psychopharmacol; 2016 Jun; 36(3):213-21. PubMed ID: 27043121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of ibudilast on oxycodone-induced analgesia and subjective effects in opioid-dependent volunteers.
    Cooper ZD; Johnson KW; Vosburg SK; Sullivan MA; Manubay J; Martinez D; Jones JD; Saccone PA; Comer SD
    Drug Alcohol Depend; 2017 Sep; 178():340-347. PubMed ID: 28688296
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of acute topiramate dosing on methamphetamine-induced subjective mood.
    Johnson BA; Roache JD; Ait-Daoud N; Wells LT; Wallace CL; Dawes MA; Liu L; Wang XQ
    Int J Neuropsychopharmacol; 2007 Feb; 10(1):85-98. PubMed ID: 16448579
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers.
    Cooper ZD; Johnson KW; Pavlicova M; Glass A; Vosburg SK; Sullivan MA; Manubay JM; Martinez DM; Jones JD; Saccone PA; Comer SD
    Addict Biol; 2016 Jul; 21(4):895-903. PubMed ID: 25975386
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Physiological and subjective effects of acute intranasal methamphetamine during extended-release alprazolam maintenance.
    Lile JA; Stoops WW; Glaser PE; Hays LR; Rush CR
    Drug Alcohol Depend; 2011 Dec; 119(3):187-93. PubMed ID: 21737214
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The glial cell modulator and phosphodiesterase inhibitor, AV411 (ibudilast), attenuates prime- and stress-induced methamphetamine relapse.
    Beardsley PM; Shelton KL; Hendrick E; Johnson KW
    Eur J Pharmacol; 2010 Jul; 637(1-3):102-8. PubMed ID: 20399770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cigarette smoking as a target for potentiating outcomes for methamphetamine abuse treatment.
    Brensilver M; Heinzerling KG; Swanson AN; Telesca D; Furst BA; Shoptaw SJ
    Drug Alcohol Rev; 2013 Jan; 32(1):96-9. PubMed ID: 22385210
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Naltrexone moderates the relationship between cue-induced craving and subjective response to methamphetamine in individuals with methamphetamine use disorder.
    Roche DJO; Worley MJ; Courtney KE; Bujarski S; London ED; Shoptaw S; Ray LA
    Psychopharmacology (Berl); 2017 Jul; 234(13):1997-2007. PubMed ID: 28357460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder.
    Ling W; Chang L; Hillhouse M; Ang A; Striebel J; Jenkins J; Hernandez J; Olaer M; Mooney L; Reed S; Fukaya E; Kogachi S; Alicata D; Holmes N; Esagoff A
    Addiction; 2014 Sep; 109(9):1489-500. PubMed ID: 24825486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Poor response to sertraline in methamphetamine dependence is associated with sustained craving for methamphetamine.
    Zorick T; Sugar CA; Hellemann G; Shoptaw S; London ED
    Drug Alcohol Depend; 2011 Nov; 118(2-3):500-3. PubMed ID: 21592681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimating the intake of abused methamphetamines using experimenter-administered deuterium labeled R-methamphetamine: selection of the R-methamphetamine dose.
    Li L; Lopez JC; Galloway GP; Baggott MJ; Everhart T; Mendelson J
    Ther Drug Monit; 2010 Aug; 32(4):504-7. PubMed ID: 20592647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of isradipine, a dihydropyridine-class calcium-channel antagonist, on d-methamphetamine's subjective and reinforcing effects.
    Johnson BA; Roache JD; Ait-Daoud N; Wallace C; Wells L; Dawes M; Wang Y
    Int J Neuropsychopharmacol; 2005 Jun; 8(2):203-13. PubMed ID: 15850499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, placebo-controlled trial of sustained-release dextroamphetamine for treatment of methamphetamine addiction.
    Galloway GP; Buscemi R; Coyle JR; Flower K; Siegrist JD; Fiske LA; Baggott MJ; Li L; Polcin D; Chen CY; Mendelson J
    Clin Pharmacol Ther; 2011 Feb; 89(2):276-82. PubMed ID: 21178989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving.
    Newton TF; Roache JD; De La Garza R; Fong T; Wallace CL; Li SH; Elkashef A; Chiang N; Kahn R
    Neuropsychopharmacology; 2006 Jul; 31(7):1537-44. PubMed ID: 16319910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subjective and physiological effects of acute intranasal methamphetamine during d-amphetamine maintenance.
    Rush CR; Stoops WW; Lile JA; Glaser PE; Hays LR
    Psychopharmacology (Berl); 2011 Apr; 214(3):665-74. PubMed ID: 21072503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.